How Will Trump’s Cuts to US Agencies Affect the Pharma Industry?
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
US President Donald Trump's first few months in his second term have brought significant controversy and concerns for the pharma industry. The introduction of the Department of Government Efficiency (DOGE) has meant major cuts have been made to all government health agencies, including the FDA, Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH). The Trump administration has defended these changes, and claimed they have been implemented to improve efficiency, streamline the government, and reduce waste. While lawsuits have attempted to slow and stop these changes, the pharma industry has concerns how the workforce cuts and changes will affect their relationship with the government agencies.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Product Type reports